AHR and neoplasm: The results with three TNBC lines (BP1, Hs578T, MDA-MB-231) and an aggressive triple negative inflammatory breast cancer line (SUM149), using molecular (siAHR, inducible shAHR, ectopic AHRR expression, and CRISPR-Cas9 gene editing) and pharmacological (AHR competitive inhibitors CH223191 and CB7993113) were completely consistent, i.e., AHR inhibition reduced all markers of tumor aggression.